Welcome to the iCAD Investors Page

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".

Recent Press Releases

December 7, 2018
iCAD Announces FDA Clearance of ProFound AI™ for Digital Breast Tomosynthesis

November 26, 2018
iCAD Unveils ProFound AI™ for Digital Breast Tomosynthesis at RSNA 2018

November 13, 2018
iCAD Reports Third Quarter 2018 Financial Results

November 9, 2018
iCAD Announces Retirement of CEO, Ken Ferry

November 6, 2018
iCAD to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results on Tuesday, November 13th

LifeSci Advisors

Jeremy Feffer
917-749-1494

jeremy@lifesciadvisors.com

Media Inquiries

ARPR, LLC
Paul Barren
855.300.8209 ext 126
paul@arpr.com

iCAD is committed to corporate sustainability and to making a difference for our environment.

* See all Financial Press Releases

Recent Events and Webcasts

November 13, 2018
4:30 pm ET
iCAD to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results

August 14, 2018
4:30 pm PT
iCAD To Report Second Quarter and Six Months Ended June 30, 2018 Financial Results

May 14, 2018
4:30 pm PT
iCAD To Report First Quarter 2018 Financial Results

March 22, 2018
4:30 pm ET
iCAD To Report Fourth Quarter and Fiscal 2017 Financial Results

November 8, 2017
4:30 pm ET
iCAD To Report Third Quarter 2017 Financial Results

* See all Events & Webcasts

CONNECT

© 2018, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo,, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.